What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial, RCT).

What question did this study set out to answer?

This research aims to validate IWG23-defined PB-CR and response criteria in patients with myeloid malignancies.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Multivariable analysis demonstrates IWG23 response criteria predict survival in AML, MDS, and CMML, suggesting PB-CR may avoid invasive assessments.

This research aims to validate IWG23-defined PB-CR and response criteria in patients with myeloid malignancies.
Analyzed data from 2,042 patients in the AML-001 trial and the Austrian Myeloid Registry.
Patients were grouped based on diagnosis and first-line therapy received.
Overall survival was calculated using Kaplan-Meier and Cox modeling for multivariable adjustment.
78% of patients had complete data for analysis, with diagnoses including AML (63%), CMML (14%), and MDS (23%).
Adjacent overall survival for first-line therapy was reported as 21.5 months for intensive chemotherapy and varying for other regimens.
PB-CR was achieved by varying percentages across treatment groups with azacitidine and venetoclax showing improved outcomes.

Pleyer et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Multivariable analysis demonstrates IWG23 response criteria predict survival in AML, MDS, and CMML, suggesting PB-CR may avoid invasive assessments.